Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Keunchil ParkPasi A JӓnneDong-Wan KimJi-Youn HanMing-Fang WuJong-Seok LeeJin-Hyoung KangDae Ho LeeByoung Chul ChoChong-Jen YuYong Kek PangEnriqueta FelipHyunjin KimEunhye BaekYoung Su NohPublished in: Cancer (2021)
Olmutinib has meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer who received previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy.